• Noah D Silverberg, Paul K Crane, Kristen Dams-O'Connor, James Holdnack, Brian J Ivins, Rael T Lange, Geoffrey T Manley, Michael McCrea, and Grant L Iverson.
• 1 Department of Medicine, Division of Physical Medicine and Rehabilitation, University of British Columbia , and GF Strong Rehab Centre, Vancouver, British Columbia, Canada, and Department of Physical Medicine and Rehabilitation, Harvard Medical School, and Red Sox Foundation and Massachusetts General Hospital Home Base Program, Boston, Massachusetts.
• J. Neurotrauma. 2017 Jan 15; 34 (2): 363-371.

AbstractCognitive impairment is a core clinical feature of traumatic brain injury (TBI). After TBI, cognition is a key determinant of post-injury productivity, outcome, and quality of life. As a final common pathway of diverse molecular and microstructural TBI mechanisms, cognition is an ideal endpoint in clinical trials involving many candidate drugs and nonpharmacological interventions. Cognition can be reliably measured with performance-based neuropsychological tests that have greater granularity than crude rating scales, such as the Glasgow Outcome Scale-Extended, which remain the standard for clinical trials. Remarkably, however, there is no well-defined, widely accepted, and validated cognition endpoint for TBI clinical trials. A single cognition endpoint that has excellent measurement precision across a wide functional range and is sensitive to the detection of small improvements (and declines) in cognitive functioning would enhance the power and precision of TBI clinical trials and accelerate drug development research. We outline methodologies for deriving a cognition composite score and a research program for validation. Finally, we discuss regulatory issues and the limitations of a cognition endpoint.

22 keywords...

hide…